Shanghai Junshi Biosciences Receives Regular Approval for COVID-19 Drug

Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an announcement.

Shanghai Junshi Biosciences Co., Ltd. announced that its subsidiary, Shanghai Vinnerna Biosciences Co., Ltd., received regular approval from the National Medical Products Administration for Deuremidevir Hydrobromide Tablets, marketed under the trade name MINDEWEI, for treating mild to moderate COVID-19. The approval is supported by clinical studies demonstrating the drug’s effectiveness in alleviating symptoms, shortening disease duration, and reducing severe cases, particularly among at-risk groups. The drug has been included in national reimbursement schemes and shows significant antiviral activity without notable drug-drug interactions, offering a safer treatment option for special groups.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. operates in the biopharmaceutical industry, focusing on the development of innovative drugs, with a particular emphasis on the treatment of diseases, including COVID-19. The company works in collaboration with various institutes and has included its products in national medical insurance schemes.

YTD Price Performance: -6.74%

Average Trading Volume: 1,324,491

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$23.34B

For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.